Medicare’s new weight-loss drug program offers affordable access to GLP-1 medication for seniors, marking a significant shift in healthcare coverage and efforts to combat obesity.
| PULSE POINTS |
❓ WHAT HAPPENED: Medicare’s first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost. 📰 DETAIL: On Wednesday, Medicare & Medicaid Services launched a new program allowing Americans aged 65 and older to access weight-loss drugs at a reduced cost of $50 a month, starting with an 18-month trial period. This is the first time Medicare has offered coverage for GLP-1 weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound. Previously, Medicare only covered these medications when prescribed for specified conditions, such as cardiovascular issues and severe fatty liver disease. 💬 KEY QUOTE: “This is a big win. For decades, medicine has failed to recognize obesity as a disease. Even with restrictions, we’ll be able to offer medications to many patients for the first time.” – Dr. Christina Nguyen, Knownwell Clinic in Atlanta, Georgia 🎯 IMPACT: The new program is expected to benefit millions of seniors and generate billions in revenue. The program is also expected to significantly reduce out-of-pocket costs for patients. While the program has been hailed as a step forward in the fight against obesity, health experts have advised against completely relying on GLP-1 drugs to lose weight, citing the negative potential to lose muscle, rather than just excess fat. “This is an important access development, but older adults should approach GLP-1 therapy as part of a comprehensive obesity-care plan, not as a stand-alone medication… For older adults, the main concern is not simply pounds lost, but what type of weight is lost,” said Dr. John Batsis, Associate Professor at the Division of Geriatric Medicine at the University of North Carolina. 👀 FLASHBACK: In November last year, President Donald J. Trump cut a deal to lower the price of weight loss medications. “Until now, [GLP-1 drugs] have [not] been covered by Medicare for weight loss and they’ve only rarely been covered by Medicaid… They’ve often cost consumers more than $1,000 per month, and some a lot more than that. Americans have been spending as much as 520 percent for Zepbound and 1,400 percent more for Wegovy than patients in Europe,” the President noted at the time. |
Join Pulse+ to comment below, and receive exclusive e-mail analyses.
.jpg){kind=link}
